BRUSSELS, April 16 (Reuters) - OncoMethylome Sciences SA begins MGMT gene promoter methylation testing in a recently started Phase III clinical trial for the U.S.-based, Radiotherapy Oncology Group in newly diagnosed brain tumors (glioblastoma).
BRUSSELS, April 16 (Reuters) - OncoMethylome Sciences SA begins MGMT gene promoter methylation testing in a recently started Phase III clinical trial for the U.S.-based, Radiotherapy Oncology Group in newly diagnosed brain tumors (glioblastoma).
